Navigation Links
Children's National researchers develop novel anti-tumor vaccine
Date:10/2/2008

WASHINGTON, DCA novel anti-tumor vaccine for neuroblastoma and melanoma developed by scientists and clinicians at Children's National Medical Center in collaboration with investigators from the University of Iowa is showing significant impact on tumor growth in mice, according to new research published in the October edition of the research journal Cancer Immunology, Immunotherapy. The vaccine uses the tumor's own protein to induce an immune system response, allowing for a personalized approach to treatment.

The vaccine and delivery system, developed in the laboratory of Children's National Chief of General and Thoracic Surgery Anthony Sandler, MD, involves the creation of synthetic microparticles known as "immune stimulatory antigen loaded particles" (ISAPs), that consist of tumor antigens (proteins) from the specific tumor to be targeted, as well as immune stimulatory agents. The ISAPs are detected and engulfed by specialized immune cells and sensed to be immune-stimulating "foreign bodies."

The study shows that ISAPs are effective at blocking the growth of tumors in mice by inducing activation of immune cells that then stimulate the immune system to specifically target the tumor whose antigens match those that are loaded in the particles known as tumor specific immunity.

The research team also discovered, however, that the impact of ISAPs on tumor growth was partially mitigated by an increased presence of regulatory t-cells (T-reg) when ISAPs are introduced into the body. The researchers believe that T-regs play a key role in how the vaccine impacts tumor growth by suppressing the development of the specific immune cells needed to combat the tumor. By adding a T-reg suppressor such as cyclosphosphamide or anti-CD25 antibody, the scientists were able to have a greater impact on preventing tumor growth using the ISAP approach.

"For tumors like neuroblastoma, reduction to minimal residual disease with standard therapies like chemotherapy and/or surgical resection and subsequent treatment with this vaccine could quite possibly cure the patient of the disease in the not too distant future," said Dr. Sandler, lead author of the study. "Creation of ISAPs allows us to target our treatments to the specific tumor of interest, a capability that will more effectively combat a wide range of these tumors in a personalized fashion."


'/>"/>

Contact: Jennifer Leischer
jleische@cnmc.org
202-476-4500
Children's National Medical Center
Source:Eurekalert

Related biology news :

1. Wolves find happy hunting grounds in Yellowstone National Park
2. BIO-key(R) International to Showcase Deployed Biometric Security Applications at 2007 Biometric Technology Expo
3. ESMO International Symposium on Immunology
4. Story tips from the US Department of Energys Oak Ridge National Laboratory, September 2007
5. Office of the Director of National Intelligence, CIO to Speak at Government Security Conference
6. Director of National Intelligence to Speak at Conference
7. Singapore National Science and Technology Awards
8. Conservation International and Toyota partner to protect Philippines rain forests
9. International team shows mercury concentrations in fish respond quickly to increased deposition
10. International team shows mercury concentrations in fish respond quickly to increased deposition
11. Office of the Director of National Intelligence, CIO to Speak at Government Security Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2020)... (PRWEB) , ... August 03, 2020 , ... ... company announced a new partnership with medical equipment manufacturer, Spectrum Solutions, to provide ... clients to strengthen their laboratory supply chain for more than 10 years. Early ...
(Date:7/31/2020)... ... 2020 , ... Justin Zamirowski to lead upcoming launches of ... on Type 2 diabetes and associated comorbidities. , Justin brings over 20 years ... As Chief Commercial Officer, Justin will lead Better Therapeutics’ efforts in ...
(Date:7/18/2020)... SAN ANTONIO (PRWEB) , ... July 16, 2020 ... ... PLOS ONE that demonstrates the effectiveness of the Invictus Medical Neoasis™ active noise ... (NICU) environment. The study reported that the Neoasis™ device attenuated the alarm sounds ...
Breaking Biology News(10 mins):
(Date:8/7/2020)... ... 06, 2020 , ... VGXI, a highly regarded CDMO supporting ... purchase of greenfield for a new, expanded manufacturing facility. The site is located ... the initial acquisition, with an option to purchase an additional 21 acres for ...
(Date:7/31/2020)... ... July 29, 2020 , ... G-CON Manufacturing, the leader in ... “BUILDING FOR LIFE.” The adoption of this taglines comes at a time of ... capacity to provide patients with urgently needed vaccines and other lifesaving pharmaceutical treatments. ...
(Date:7/31/2020)... (PRWEB) , ... July 29, 2020 , ... eSource has ... inefficiencies. This webinar will cover the history of eSource, the reasons it did not ... EMR/EHR to wearables, to site source, the industry is moving towards capturing data electronically ...
(Date:7/18/2020)... ... July 16, 2020 , ... After research model surgery and catheter implantation, the ... is only the beginning of a successful study, while protecting and accessing the catheter ... Global Head of Surgery from Envigo in a live webinar ...
Breaking Biology Technology: